乳腺癌基因检测与临床实践  

Clinical practice of gene expression tests in bresat cancer

作　　者：辛灵[1] 刘倩[1] 徐玲[1] 叶京明[1] 赵建新[1] 段学宁[1] 刘荫华[1] 

机构地区：[1]北京大学第一医院外科,北京100034

出　　处：《中国实用外科杂志》2014年第1期73-76,共4页Chinese Journal of Practical Surgery

基　　金：首都临床特色应用研究项目(项目编号:Z131107002213007)

摘　　要：2013年St Gallen专家共识推荐针对乳腺癌进行基因检测,肯定多基因序列分析能够为luminal型乳腺癌进一步分类提供参考,并针对21基因检测评分的必要性进行讨论。在肿瘤基因检测研究中应用乳腺癌21基因检测和70基因检测技术,证实其对预测肿瘤预后、治疗具有价值。但是,现有条件下昂贵的费用和难以达到的技术水平限制了基因检测在临床的推广应用。2013 St Gallen Panels recommended gene expression tests in breast cancer patients, which affirmed the value of multi-gene assays in clinical management among patients with luminal disease. Two available tests, Oncotype Dx TM and MammaPrintTM, have exhibited good metric performance in the prediction of prognosis and treatment benefit of early-stage breast cancer. However, these genomic predictors are still not ready for routine clinical practice for high cost and inaccessible technology in most area. We now focus on the hot issues of gene expressions and discuss the current status and limitation in clinical practice as follows.

关 键 词：乳腺癌 21基因检测 70基因检测 

分 类 号：R6[医药卫生—外科学]